2009
DOI: 10.1038/sj.bjc.6605155
|View full text |Cite|
|
Sign up to set email alerts
|

Clinical outcome data for symptomatic breast cancer: the breast cancer clinical outcome measures (BCCOM) project

Abstract: BACKGROUND: Data collection for screen-detected breast cancer in the United Kingdom is fully funded, which has led to improvements in clinical practice. However, data on symptomatic cancer are deficient, and the aim of this project was to monitor the current practice. METHODS: A data set was designed together with surrogate outcome measures to reflect best practice. Data from cancer registries initially required the consent of clinicians, but in the third year anonymised data were available. RESULTS: The quali… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
23
0

Year Published

2010
2010
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(24 citation statements)
references
References 12 publications
1
23
0
Order By: Relevance
“…Surgical registries can provide essential clinical and cost‐effectiveness data for policy and guidelines development . They also help develop (inter)national research collaborations as well as promote patient choice, trust, and transparency . Other benefits include facilitating inter(national) benchmarking and personal audit .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Surgical registries can provide essential clinical and cost‐effectiveness data for policy and guidelines development . They also help develop (inter)national research collaborations as well as promote patient choice, trust, and transparency . Other benefits include facilitating inter(national) benchmarking and personal audit .…”
Section: Discussionmentioning
confidence: 99%
“…Other benefits include facilitating inter(national) benchmarking and personal audit . Successful registries have helped drive healthcare quality improvement, improve patient safety, and allowed service providers to monitor quality and identify variations in practice . It has also been recognized that registry data can serve as a valuable alternative to randomized trials .…”
Section: Discussionmentioning
confidence: 99%
“…Frequently cited pathologic data from US and Europe, such as the US Surveillance, Epidemiology and End Results (SEER) database, Breast Cancer Clinical Outcome Measures (BCCOM) database, the European ONCOPOOL database, and other large‐scale population studies,32–38 were used to compare the characteristics between the Western and Chinese. In detail, the Caucasian data of tumor size, pathologic type, AJCC stage, ER and PR status from US SEER database and HER2 status data from the IMPATH laboratories were used as US representative data 32, 34, 37.…”
Section: Methodsmentioning
confidence: 99%
“…In detail, the Caucasian data of tumor size, pathologic type, AJCC stage, ER and PR status from US SEER database and HER2 status data from the IMPATH laboratories were used as US representative data 32, 34, 37. Tumor size data from BCCOM database,33 pathologic type from ONCOPOOL database,35 AJCC stage, ER and PR status from Switzerland36, HER2 status from England38 were used as Europe representative data.…”
Section: Methodsmentioning
confidence: 99%
“…(1) According to World Health Organization 2010, there were about 519,000 women who die from breast cancer annually and about one million of women develop breast cancer each year. (2,3) The most recent study by Ibrahim et al (4) reported that cancer incidence rates based on national and regional level of Egypt revealed 157 per 100,000 among females. The commonest site was breast (32.0%) and the study added that by 2050, this incidence will be a 3-fold increase cancer relative to 2013 estimated rates.…”
Section: Introductionmentioning
confidence: 99%